KarlDLewisMD

Oncology • Aurora, CO

Associate Professor, Medicine, University of Colorado School of Medicine

Join to view full profile

Dr. Lewis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lewis' full profile

Already have an account?

Office
12605 E 16th Ave
Aurora, CO 80045
Phone+1 720-848-0000

Education & Training

University of ColoradoFellowship, Hematology and Medical Oncology, 2002 - 2004
University of California (Irvine)Residency, Internal Medicine, 1999 - 2002
Albany Medical CollegeClass of 1999

Certifications & Licensure

CA State Medical License 2001 - Present
CO State Medical License 2003 - 2025

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2011 Jan 18
Completed
Phase 2
Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients Start of enrollment: 2013 Apr 01
Completed
Phase 1
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) Start of enrollment: 2019 Apr 01
Active, not recruiting
Phase 1
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer Start of enrollment: 2019 Oct 08
Active, not recruiting
Phase 2
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) Start of enrollment: 2019 Jul 18
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, ...
Brett G M Hughes, Alexander Guminski, Samantha Bowyer, Michael R Migden, Chrysalyne D Schmults
Journal of the American Academy of Dermatology. 2025-01-01
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1).
Ulka N Vaishampayan, Jameel Muzaffar, Ira Winer, Seth D Rosen, Christoper J Hoimes
Journal for Immunotherapy of Cancer. 2024-11-20
Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling.
Jacqueline A Turner, Robert J Van Gulick, William A Robinson, Tariq Mughal, Richard P Tobin
International Journal of Cancer. 2024-11-15

Lectures

Effects of sonidegib dose reduction or delay in locally advanced basal cell carcinoma: 42-month data from BOLT.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Next-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage CancersMay 26th, 2022
FDA Approves Libtayo for Advanced Basal Cell CarcinomaFebruary 10th, 2021
FDA Approves Libtayo for Locally Advanced and Metastatic Basal Cell CarcinomaFebruary 10th, 2021
Join now to see all